CD34+ cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer

Journal of Hematotherapy and Stem Cell Research

Volumn 8, Issue 4, 1999, Pages 357-363

  Papadopoulos, Kyriakos P ^a   Ayello, Janet ^a   Reiss, Robert F ^a   Troxel, Andrea ^a   Kaufman, Elizabeth ^a   Vahdat, Linda T ^a   Antman, Karen H ^a   Hesdorffer, Charles S ^a,b  

^a College of Physicians and Surgeons ^*  (United States)

^b Division of Medical Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; PACLITAXEL; THIOTEPA;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HEMODYNAMIC PARAMETERS; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; METASTASIS; NEUTROPHIL; PRIORITY JOURNAL; THROMBOCYTE COUNT;

ADULT; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD CELL COUNT; BREAST NEOPLASMS; CARBOPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MELPHALAN; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; THIOTEPA; TRANSPLANTATION, AUTOLOGOUS;

EID: 0032694859     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: 10.1089/152581699320117     Document Type: Article

References (31)

1. Bensinger W, F Appelbaum, S Rowley, et al. (1995). Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 13:2547-2555.
2. Haas R, R Mohle, S Murea, et al. (1994). Characterization of peripheral blood progenitor cells mobilized by cytotoxic chemotherapy and recombinant human granulocyte colony-stimulating factor. J Hematother 3:323-330.
3. + cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell support. J Hematother 6:61-68.
4. Chabannon C, A Le Coroller, C Faucher, et al. (1995). Patient condition affects the collection of peripheral blood progenitors after priming with recombinant granulocyte colony-stimulating factor. J Hematother 4:171-179.
5. Schwartzberg L, R Birch, R Blanco, et al. (1993). Rapid and sustained hematopoietic reconstitution by peripheral blood stem cell infusion alone following high-dose chemotherapy. Bone Marrow Transplant 11:369-374.
6. van der Wall E, DJ Richel, MJ Holtkamp, et al. (1994). Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: effect of graft size. Ann Oncol 5:795-802.
7. Zimmerman T, W Lee, J Bender, et al. (1995). Quantititive CD34 analysis may be used to guide peripheral blood stem cell harvest. Bone Marrow Transplant 9:439-444.
8. + cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation. Transfusion 38:385-391.
9. Vahdat LT, K Papadopoulos, C Balmaceda, et al. (1998). Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer. Clin Cancer Res 4:1689-1695.
10. Ayello J, C Hesdorffer and R Reiss. (1995). A semiautomated technique for volume reduction of stem cell suspensions for autotransplantation. J Hematother 4:545-549.
11. 2 may not require stem cell support. Blood 90 (Suppl 1):263b.
12. + cell enumeration in blood and leukapheresis products: report from the second Nordic Workshop. Nordic Stem Cell Laboratory Group (NSCL-G). J Hematother 5:237-245.
13. Hortobagyi GN and FA Holmes. (1996). Single-agent paclitaxel for the treatment of breast cancer: an overview. Semin Oncol 23(Suppl 1):4-9.
14. Rowinsky EK, EA Eisenhauer, V Chaudhry, et al. (1993). Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20(Suppl 3):1-15.
15. Rowinsky EK, PJ Burke, JE Karp, et al. (1989). Phase I and pharmacodynamic study of Taxol in refractory acute leukemias. Cancer Res 49:4640-4647.
16. Holmes FA. (1995). Update: the MD. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma. Semin Oncol 22(Suppl 8):9-15.
17. Seidman AD, BS Reichman, JP Crown, et al. (1993). Taxol plus recombinant human granulocyte-colony stimulating factor as initial and as salvage chemotherapy for metastatic breast cancer: a preliminary report. J Natl Cancer Inst Monographs 15:171-175.
18. (+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 91:3148-3155.
19. Alcorn MJ, TL Holyoake, L Richmond, et al. (1996). CD34-positive cells isolated from cryopreserved peripheral-blood progenitor cells can be expanded ex vivo and used for transplantation with little or no toxicity. J Clin Oncol 14:1839-1847.
20. + cells in autologous stem cell transplantation for breast cancer. Blood 87:1687-1691.
21. Samuels BL and JD Bitran. (1995). High-dose intravenous melphalan: a review. J Clin Oncol 13:1786-1799.
22. Harousseau JL, N Milpied, JP Laporte, et al. (1992). Double-intensive therapy in high-risk multiple myeloma. Blood 79:2827-2833.
23. Lokhorst HM, OJ Meuwissen, LF Verdonck, et al. (1992). High-risk multiple myeloma treated with high-dose melphalan. J Clin Oncol 10:47-51.
24. Cunningham D, L Paz-Ares, ME Gore, et al. (1994). High-dose melphalan for multiple myeloma: long-term follow-up data. J Clin Oncol 12:764-768.
25. Vesole DH, B Barlogie, S Jagannath, et al. (1994). High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood 84:950-956.
26. Bitran JD, B Samuels, L Klein, et al. (1996). Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer. Bone Marrow Transplant 17:157-162.
27. Ayash LJ, A Elias, G Schwartz, et al. (1996). Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin. J Clin Oncol 14:2984-2992.
28. Dreger P, M Kloss, B Petersen, et al. (1995). Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 86:3970-3978.
29. Glaspy JA, EJ Shpall, CF LeMaistre, et al. (1997). Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood 90:2939-2951.
30. + peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 4:84-92.
31. Weaver C, T Moss, L Schwartzberg, et al. (1998). High-dose chemotherapy in patients with breast cancer: evaluation of infusing peripheral blood stem cells containing occult tumor cells. Bone Marrow Transplant 21: 1117-1124.